Evidence map›Paper›PMID 23563667›Full record

ReviewHandbook of experimental pharmacology2013

Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

S B Russo, J S Ross, L A Cowart

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Nutrition research and practice · 2023
    Article
  12. Review
  13. Review
  14. Article
  15. ORMDL in metabolic health and disease.Pharmacology & therapeutics · 2023
    Review
  16. Review
  17. Article
  18. Sphingolipids in neurodegenerative diseases.Frontiers in neuroscience · 2023
    Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

S B RussoDepartment of Biochemistry and Molecular Biology, The Medical University of South Carolina, Charleston, SC, USA.
J S Ross
L A Cowart
Medical University of South Carolina · USRalph H. Johnson VA Medical Center · US

Funding

MUSC Minority Student Development ProgramR25GM072643 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE, RINKER, JENNIFER ANNE · 2005 to 2023
$5.8M
Metabolic Determinants of Cardiac Bioactive Sphingolipids in Lipid OverloadF30DK092125 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RUSSO, SARAH BRICE · 2011 to 2013
$111k
NIDDK NIH HHS F30 DK092125NIDDK NIH HHS F30DK092125NIGMS NIH HHS R25 GM072643
6 · The paper itself

Abstract

Metabolic disease, including obesity and type 2 diabetes, constitutes a major emerging health crisis in Western nations. Although the symptoms and clinical pathology and physiology of these conditions are well understood, the molecular mechanisms underlying the disease process have largely remained obscure. Sphingolipids, a lipid class with both signaling and structural properties, have recently emerged as key players in most major tissues affected by diabetes and are required components in the molecular etiology of this disease. Indeed, sphingolipids have been shown to mediate loss of insulin sensitivity, to promote the characteristic diabetic proinflammatory state, and to induce cell death and dysfunction in important organs such as the pancreas and heart. Furthermore, plasma sphingolipid levels are emerging as potential biomarkers for the decompensation of insulin resistance to frank type 2 diabetes. Despite these discoveries, the roles of specific sphingolipid species and sphingolipid metabolic pathways remain obscure, and newly developed experimental approaches must be employed to elucidate the detailed molecular mechanisms necessary for rational drug development and other clinical applications.

Indexed as

Signal TransductionAdipose TissueAnimalsBiomarkersDiabetes Mellitus, Type 2HumansInsulin ResistanceMetabolic DiseasesMuscle, SkeletalMyocardiumObesityPancreasSphingolipidsBiomarkersSphingolipids

Identifiers

PMID23563667
PMCPMC4091661
OpenAlexW1145903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.